DR LOVE: We have seen some data looking at bevacizumab in mesothelioma, also, obviously, an anti-angiogenic. Where do we stand with that? And is that a strategy that you think would be reasonable to utilize outside a trial setting in mesothelioma?

DR BLUMENSCHEIN: So you’re referencing the trial I think that came out of Europe, which was pemetrexed/cisplatin with or without the addition of bevacizumab. And actually, that study was a positive trial. I think the median overall survival was approximately a year and a half. And the other interesting part is that the standard of care arm, which is pemetrexed/cisplatin, did better than we traditionally have seen, also exceeding the 1-year median survival we’ve traditionally seen with that combination. But yes, to get to your point, I do think that’s a potential therapeutic option for patients who are otherwise good candidates for bevacizumab. They don’t have a bleeding diathesis. Kidney function’s good. Blood pressure’s controlled. It doesn’t look like there’s something near a blood vessel, which would be worrisome for a potential bleed.

First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) for EGFR mutation-positive non-small cell lung cancer (NSCLC)

Osimertinib and treatment options for patients with disease progression on an EGFR TKI

Other targetable mutations in NSCLC: ALK rearrangement; MET exon 14 splice mutation

Application of immune checkpoint inhibitors in NSCLC

Systemic and localized treatment approaches for NSCLC

Small cell lung cancer, mesothelioma and squamous NSCLC